Literature DB >> 7771913

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

T Spencer1, T Wilens, J Biederman, S V Faraone, J S Ablon, K Lapey.   

Abstract

BACKGROUND: There are few controlled studies of methylphenidate hydrochloride in adults with attention-deficit hyperactivity disorder (ADHD), and their results have been equivocal. The discrepancies among these studies may be related to low doses, diagnostic uncertainties, and lack of attention to comorbid disorders.
METHODS: We conducted a randomized, 7-week, placebo-controlled, crossover study of methylphenidate in 23 adult patients with DSM-III-R ADHD using standardized instruments for diagnosis, separate assessments of ADHD and depressive and anxiety symptoms, and a robust daily dose of methylphenidate hydrochloride, 1.0 mg/kg per day.
RESULTS: We found a marked therapeutic response for methylphenidate treatment of ADHD symptoms that exceeded the placebo response (78% vs 4%, P < .0001). Response to methylphenidate was independent of gender, psychiatric comorbidity with anxiety or moderate depression, or family history of psychiatric disorders.
CONCLUSION: Robust doses of methylphenidate are effective in the treatment of adult ADHD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7771913     DOI: 10.1001/archpsyc.1995.03950180020004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  67 in total

Review 1.  Adult attention deficit hyperactivity disorder.

Authors:  S V Faraone; M T Tsuang
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Bupropion for adults with attention deficit hyperactivity disorder.

Authors:  Jeffery H Newcorn
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

Review 3.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 4.  Interventions to address the academic impairment of children and adolescents with ADHD.

Authors:  Veronica L Raggi; Andrea M Chronis
Journal:  Clin Child Fam Psychol Rev       Date:  2006-06

Review 5.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

6.  [Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder].

Authors:  E Sobanski; B Alm
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

7.  Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.

Authors:  Danielle C Turner; Andrew D Blackwell; Jonathan H Dowson; Andrew McLean; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

8.  Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Authors:  Suma M Krishnan; Michael Pennick; Jeffrey G Stark
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

10.  European clinical guidelines for hyperkinetic disorder -- first upgrade.

Authors:  Eric Taylor; Manfred Döpfner; Joseph Sergeant; Philip Asherson; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Aribert Rothenberger; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.